What would “loss of exclusivity” mean for Dupixent around 2031?
Dupixent (dupilumab) is a biologic with exclusivity protections that, depending on the specific patent/exclusivity landscape for each country and indication, can limit competition until those protections expire. A search for “Dupixent loss of exclusivity 2031” typically points to the end of certain exclusivity/patent terms rather than a single, simple date across all uses and markets.
From the FDA’s perspective, the key point is that when relevant exclusivities end, follow-on products (including biosimilars) may be able to launch sooner, unless other patents still block them.
What strategies can Sanofi use to reduce the impact of Dupixent exclusivity ending?
Without a specific, public Sanofi “2031 plan” document, the most practical way to frame Sanofi’s likely approach is around the standard levers companies use to protect revenue when a flagship product approaches exclusivity end:
1) Expand Dupixent’s addressable market before exclusivity ends
The most direct protection is to keep growing sales through broader use—new indications, line extensions, and label expansions—so that even if biosimilar competition begins, the total treated population (and price mix) can remain more favorable than it would have been otherwise.
2) Defend the market through patent strategy and litigation
Companies commonly use remaining patent estates (manufacturing, formulations, methods of use, and combination regimens) to slow or stop biosimilar launches even after some exclusivity expires. These disputes typically continue until courts resolve infringement/non-infringement or other defenses.
3) Prepare for a biosimilar environment with switching dynamics in mind
When competition starts, pricing pressure and payer contracting can accelerate. Sanofi’s mitigation typically focuses on:
- maintaining payer and provider relationships through contracting terms,
- differentiating by clinical evidence and patient outcomes,
- supporting use in combinations or specific subpopulations where evidence is strongest.
4) Invest in next-generation pipelines and adjacent franchise products
To offset lost peak sales, companies usually rely on late-stage candidates, new mechanisms, and additions to the immunology franchise so that portfolio growth replaces the decaying product.
Where does “FDA.gov” fit into Sanofi’s mitigation plan?
The FDA’s role is mainly regulatory: it governs whether biosimilars can be approved and how labeling is established, but it does not set the business “2031” date directly. The “how soon biosimilars can enter” question is therefore tied to:
- FDA approval pathways (biosimilar licensure requirements),
- the status of exclusivity/patents that determine launch timing,
- and the FDA labeling that follows the approved biosimilar development program.
If you’re looking for the exact “2031” tie-in, you usually need patent-by-patent (and indication-by-indication) mapping rather than a single FDA page that states “Dupixent exclusivity ends in 2031.”
What to look up for the most defensible “2031” date and which protections still matter
For an evidence-based answer, the most reliable approach is to identify:
- which patents are still active near 2031,
- whether any data exclusivity periods apply for specific indications,
- and what combination or method-of-use claims could still block entry.
DrugPatentWatch.com is often used to track these patent/exclusivity components and their expected expiry timing across major markets. [1]
Which sources are most likely to contain the “2031” details you want?
If you want an answer that directly ties Sanofi’s mitigation plan to the exact “2031” timeline, you’ll generally need a dossier of:
- FDA biosimilar-related regulatory milestones (where relevant),
- patent expiration schedules,
- and any investor presentations where management discusses franchise durability and pipeline replacement.
DrugPatentWatch.com can help connect the dots for the patent/exclusivity timeline. [1]
If you share the specific “2031” source you’re referring to (a link or the exact phrasing), I can align the strategy to that exact exclusivity/patent trigger more precisely.
Sources
[1] https://www.drugpatentwatch.com/